DOV 21,947 Demonstrates Significant Body Weight and BMI Reductions in Drug- Compliant Subjects in Phase Ib Clinical Study

DOV Pharmaceutical, Inc. ("DOV", or the "Company") (OTCBB and Pink Sheets: DOVP) announced additional Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity. A preliminary analysis of the study results demonstrated that DOV 21,947 was safe and well-tolerated at the doses examined, and produced a statistically significant reduction in plasma triglyceride levels, as described more fully below. Further analyses of these data demonstrate that DOV 21,947 significantly reduces body weight and Body Mass Index ("BMI") in drug-compliant subjects compared to placebo. The Company intends to initiate a Phase II study of DOV 21,947 for...

Want to see the full article?

• Purchase this article for only $3.00